Alpha-synuclein levels in blood plasma decline with healthy aging

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Koehler, Niklas K U ^a,b   Stransky, Elke ^a   Meyer, Mirjam ^a   Gaertner, Susanne ^a   Shing, Mona ^a   Schnaidt, Martina ^c   Celej, Maria S ^e,f   Jovin, Thomas M ^e   Leyhe, Thomas ^a,d   Laske, Christoph ^a,b   Batra, Anil ^a   Buchkremer, Gerhard ^a   Fallgatter, Andreas J ^a   Wernet, Dorothee ^c   Richartz Salzburger, Elke ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

^e MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^f UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ALPHA SYNUCLEIN ANTIBODY; BETA SYNUCLEIN; BIOLOGICAL MARKER; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; SNCA PROTEIN, HUMAN;

ACIDIFICATION; AGE DISTRIBUTION; AGING; ARTICLE; BINDING AFFINITY; BINDING SITE; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOBLOTTING; LIMIT OF DETECTION; NORMAL HUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN HOMEOSTASIS; RELIABILITY; ADULT; AGED; BLOOD; GENE EXPRESSION REGULATION; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; AGING; ALPHA-SYNUCLEIN; BIOMARKERS; GENE EXPRESSION REGULATION; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84926661411     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123444     Document Type: Article

References (80)

1. Eller M, Williams DR (2011) alpha-Synuclein in Parkinson disease and other neurodegenerative disorders. Clin Chem Lab Med 49:403-408. doi: 10.1515/CCLM.2011.077 PMID: 21342025
2. Kasuga K, Nishizawa M, Ikeuchi T (2012) alpha-Synuclein as CSF and Blood Biomarker of Dementia with Lewy Bodies. Int J Alzheimers Dis 2012:437025. doi: 10.1155/2012/437025 PMID: 23056991
3. David DC, Ollikainen N, Trinidad JC, Cary MP, Burlingame AL, et al. (2010) Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol 8:e1000450. doi: 10.1371/journal.pbio. 1000450 PMID: 20711477
4. Ben-Zvi A, Miller EA, Morimoto RI (2009) Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A 106:14914-14919. doi: 10.1073/pnas. 0902882106 PMID: 19706382
5. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G (2013) The hallmarks of aging. Cell 153:1194-1217. doi: 10.1016/j.cell.2013.05.039 PMID: 23746838
6. Labbadia J, Morimoto RI (2014) Proteostasis and longevity: when does aging really begin? F1000Prime Rep 6:7. doi: 10.12703/P6-7 PMID: 24592319
7. Yung RL, Julius A (2008) Epigenetics, aging, and autoimmunity. Autoimmunity 41:329-335. doi: 10. 1080/08916930802024889 PMID: 18432411
8. Richartz-Salzburger E, Stransky E, Laske C, Kohler N (2010) [Premature immunosenescence: a pathogenetic factor in Alzheimer's disease? J. Nervenarzt 81:837-843. doi: 10.1007/s00115-009-2918-7 PMID: 20386875
9. Darvin K, Randolph A, Ovalles S, Halade D, Breeding L, et al. (2013) Plasma Protein Biomarkers of the Geriatric Syndrome of Frailty. J Gerontol A Biol Sci Med Sci.
10. Simm A, Nass N, Bartling B, Hofmann B, Silber RE, et al. (2008) Potential biomarkers of ageing. Biol Chem 389:257-265. doi: 10.1515/BC.2008.034 PMID: 18208349
11. Kim S, Parks CG, Xu Z, Carswell G, DeRoo LA, et al. (2012) Association between genetic variants in DNA and histone methylation and telomere length. PLoS One 7:e40504. doi: 10.1371/journal.pone. 0040504 PMID: 22792358
12. Colom-Cadena M, Gelpi E, Charif S, Belbin O, Blesa R, et al. (2013) Confluence of alpha-synuclein, tau, and beta-amyloid pathologies in dementia with Lewy bodies. J Neuropathol Exp Neurol 72:1203-1212. doi: 10.1097/NEN.0000000000000018 PMID: 24226269
13. Irwin DJ, Lee VM, Trojanowski JQ (2013) Parkinson's disease dementia: convergence of alphasynuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 14:626-636. doi: 10.1038/nrn3549 PMID: 23900411
14. Jellinger KA (2012) Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med 16:1166-1183. doi: 10.1111/j.1582-4934.2011.01507.x PMID: 22176890
15. Giasson BI, Lee VM, Trojanowski JQ (2003) Interactions of amyloidogenic proteins. Neuromolecular Med 4:49-58. PMID: 14528052
16. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300:636-640. PMID: 12714745
17. Costanzo M, Zurzolo C (2013) The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem J 452:1-17. doi: 10.1042/BJ20121898 PMID: 23614720
18. Jucker M, Walker LC (2011) Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70:532-540. doi: 10.1002/ana.22615 PMID: 22028219
19. Li Q, Cao C, Chackerian B, Schiller J, Gordon M, et al. (2004) Overcoming antigen masking of antiamyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. BMC Neurosci 5:21. PMID: 15186505
20. Bratic A, Larsson NG (2013) The role of mitochondria in aging. J Clin Invest 123:951-957. doi: 10. 1172/JCI64125 PMID: 23454757
21. Lee HC, Wei YH (2012) Mitochondria and aging. Adv Exp Med Biol 942:311-327. doi: 10.1007/978-94-007-2869-1-14 PMID: 22399429
22. Rott R, Szargel R, Shani V, Bisharat S, Engelender S (2013) alpha-Synuclein Ubiquitination and Novel Therapeutic Targets for Parkinson's Disease. CNS Neurol Disord Drug Targets.
23. Ebrahimi-Fakhari D, Wahlster L, McLean PJ (2012) Protein degradation pathways in Parkinson's disease: curse or blessing. Acta Neuropathol 124:153-172. doi: 10.1007/s00401-012-1004-6 PMID: 22744791
24. Dimant H, Ebrahimi-Fakhari D, McLean PJ (2012) Molecular Chaperones and Co-Chaperones in Parkinson Disease. Neuroscientist.
25. Koehler NK, Stransky E, Shing M, Gaertner S, Meyer M, et al. (2013) Altered serum IgG levels to alphasynuclein in dementia with Lewy bodies and Alzheimer's disease. PLoS One 8:e64649. doi: 10.1371/journal.pone.0064649 PMID: 23741358
26. O'Nuallain B, Williams AD, McWilliams-Koeppen HP, Acero L, Weber A, et al. (2010) Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol 30 Suppl 1:S37-42. doi: 10.1007/s10875-010-9413-6 PMID: 20405179
27. Kim YE, Hipp MS, Bracher A, Hayer-Hartl M, Hartl FU (2013) Molecular chaperone functions in protein folding and proteostasis. Annu Rev Biochem 82:323-355. doi: 10.1146/annurev-biochem-060208-092442 PMID: 23746257
28. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for disease intervention. Science 319:916-919. doi: 10.1126/science.1141448 PMID: 18276881
29. Hartl FU, Bracher A, Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature 475:324-332. doi: 10.1038/nature10317 PMID: 21776078
30. Maroteaux L, Campanelli JT, Scheller RH (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8:2804-2815. PMID: 3411354
31. Ueda K, Fukushima H, Masliah E, Xia Y, Iwai A, et al. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 90:11282-11286. PMID: 8248242
32. Hashimoto M, Yoshimoto M, Sisk A, Hsu LJ, Sundsmo M, et al. (1997) NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun 237:611-616. PMID: 9299413
33. Borghi R, Marchese R, Negro A, Marinelli L, Forloni G, et al. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett 287:65-67. PMID: 10841992
34. Kim TD, Ryu HJ, Cho HI, Yang CH, Kim J (2000) Thermal behavior of proteins: heat-resistant proteins and their heat-induced secondary structural changes. Biochemistry 39:14839-14846. PMID: 11101300
35. El-Agnaf OM, Salem SA, Paleologou KE, Cooper LJ, Fullwood NJ, et al. (2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. FASEB J 17:1945-1947. PMID: 14519670
36. Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, et al. (2013) Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 9:131-140. doi: 10.1038/nrneurol.2013.10 PMID: 23419373
37. Schapira AH (2013) Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol 26:395-400. doi: 10.1097/WCO.0b013e3283633741 PMID: 23823465
38. Chahine LM, Stern MB, Chen-Plotkin A (2014) Blood-based biomarkers for Parkinson's disease. Parkinsonism Relat Disord 20 Suppl 1:S99-103. doi: 10.1016/S1353-8020 (13) 70025-7 PMID: 24262199
39. Malek N, Swallow D, Grosset KA, Anichtchik O, Spillantini M, et al. (2014) Alpha-synuclein in peripheral tissues and body fluids as a biomarker for Parkinson's disease-a systematic review. Acta Neurol Scand.
40. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388:839-840. PMID: 9278044
41. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, et al. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 152:879-884. PMID: 9546347
42. Galpern WR, Lang AE (2006) Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 59:449-458. PMID: 16489609
43. Kotzbauer PT, Trojanowsk JQ, Lee VM (2001) Lewy body pathology in Alzheimer's disease. J Mol Neurosci 17:225-232. PMID: 11816795
44. Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ (1999) Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 45:353-357. PMID: 10072050
45. Hurtig HI, Trojanowski JQ, Galvin J, Ewbank D, Schmidt ML, et al. (2000) Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 54:1916-1921. PMID: 10822429
46. Larson ME, Sherman MA, Greimel S, Kuskowski M, Schneider JA, et al. (2012) Soluble alphasynuclein is a novel modulator of Alzheimer's disease pathophysiology. J Neurosci 32:10253-10266. doi: 10.1523/JNEUROSCI.0581-12.2012 PMID: 22836259
47. van Geel WJ, Abdo WF, Melis R, Williams S, Bloem BR, et al. (2008) A more efficient enzyme-linked immunosorbent assay for measurement of alpha-synuclein in cerebrospinal fluid. J Neurosci Methods 168:182-185. PMID: 17976734
48. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, et al. (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58:147-150. PMID: 15984012
49. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6:419-430. doi: 10.2217/bmm.12.46 PMID: 22917144
50. Sun ZF, Xiang XS, Chen Z, Zhang L, Tang BS, et al. (2013) Increase of the plasma alpha-synuclein levels in patients with multiple system atrophy. Mov Disord.
51. Smith LM, Schiess MC, Coffey MP, Klaver AC, Loeffler DA (2012) alpha-Synuclein and Anti-alpha-Synuclein Antibodies in Parkinson's Disease, Atypical Parkinson Syndromes, REM Sleep Behavior Disorder, and Healthy Controls. PLoS One 7:e52285. doi: 10.1371/journal.pone.0052285 PMID: 23284971
52. Besong-Agbo D, Wolf E, Jessen F, Oechsner M, Hametner E, et al. (2013) Naturally occurring alphasynuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169-175. doi: 10.1212/WNL.0b013e31827b90d1 PMID: 23255825
53. Gorostidi A, Bergareche A, Ruiz-Martinez J, Marti-Masso JF, Cruz M, et al. (2012) Alpha-synuclein levels in blood plasma from LRRK2 mutation carriers. PLoS One 7:e52312. doi: 10.1371/journal.pone. 0052312 PMID: 23300640
54. Duran R, Barrero FJ, Morales B, Luna JD, Ramirez M, et al. (2010) Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment. Mov Disord 25:489-493. doi: 10.1002/mds. 22928 PMID: 20063406
55. Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, et al. (2008) GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein. Proc Natl Acad Sci U S A 105:10907-10912. doi: 10.1073/pnas.0802437105 PMID: 18669654
56. Barbour R, Kling K, Anderson JP, Banducci K, Cole T, et al. (2008) Red blood cells are the major source of alpha-synuclein in blood. Neurodegener Dis 5:55-59. doi: 10.1159/000112832 PMID: 18182779
57. Mash DC, Adi N, Duque L, Pablo J, Kumar M, Ervin FR (2008) Alpha synuclein protein levels are increased in serum from recently abstinent cocaine abusers. Drug Alcohol Depend 94:246-250. PMID: 18055133
58. Tinsley RB, Kotschet K, Modesto D, Ng H, Wang Y, et al. (2010) Sensitive and specific detection of alpha-synuclein in human plasma. J Neurosci Res 88:2693-2700. doi: 10.1002/jnr.22417 PMID: 20648655
59. Mata IF, Shi M, Agarwal P, Chung KA, Edwards KL, et al. (2010) SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 67:1350-1356. doi: 10.1001/archneurol. 2010.279 PMID: 21060011
60. Shi M, Zabetian CP, Hancock AM, Ginghina C, Hong Z, et al. (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480:78-82. doi: 10.1016/j. neulet.2010.06.009 PMID: 20540987
61. Fjorback AW, Varming K, Jensen PH (2007) Determination of alpha-synuclein concentration in human plasma using ELISA. Scand J Clin Lab Invest 67:431-435. PMID: 17558898
62. Bonsch D, Greifenberg V, Bayerlein K, Biermann T, Reulbach U, et al. (2005) Alpha-synuclein protein levels are increased in alcoholic patients and are linked to craving. Alcohol Clin Exp Res 29:763-765. PMID: 15897720
63. Brighina L, Prigione A, Begni B, Galbussera A, Andreoni S, et al. (2010) Lymphomonocyte alphasynuclein levels in aging and in Parkinson disease. Neurobiol Aging 31:884-885. doi: 10.1016/j. neurobiolaging.2008.06.010 PMID: 18676060
64. Martinez-Vicente M, Sovak G, Cuervo AM (2005) Protein degradation and aging. Exp Gerontol 40:622-633. PMID: 16125351
65. Lee CK, Klopp RG, Weindruch R, Prolla TA (1999) Gene expression profile of aging and its retardation by caloric restriction. Science 285:1390-1393. PMID: 10464095
66. Tanaka H, Seals DR (2008) Endurance exercise performance in Masters athletes: age-associated changes and underlying physiological mechanisms. J Physiol 586:55-63. PMID: 17717011
67. Schulz R, Curnow C (1988) Peak performance and age among superathletes: track and field, swimming, baseball, tennis, and golf. J Gerontol 43:P113-120. PMID: 3418037
68. Kokhan VS, Afanasyeva MA, Van'kin GI (2012) alpha-Synuclein knockout mice have cognitive impairments. Behav Brain Res 231:226-230. doi: 10.1016/j.bbr.2012.03.026 PMID: 22469626
69. Clayton DF, George JM (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 58:120-129. PMID: 10491577
70. Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, et al. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25:239-252. PMID: 10707987
71. Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, et al. (2006) Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 21:541-548. PMID: 16298531
72. Michell AW, Luheshi LM, Barker RA (2005) Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. Neurosci Lett 381:294-298. PMID: 15896487
73. Gardai SJ, Mao W, Schule B, Babcock M, Schoebel S, et al. (2013) Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease. PLoS One 8:e71634. doi: 10.1371/journal.pone.0071634 PMID: 24058406
74. Goldberg MS, Lansbury PT Jr (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2:E115-119. PMID: 10878819
75. Fuchs J, Nilsson C, Kachergus J, Munz M, Larsson EM, et al. (2007) Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 68:916-922. PMID: 17251522
76. Kasten M, Klein C (2013) The many faces of alpha-synuclein mutations. Mov Disord 28:697-701. doi: 10.1002/mds.25499 PMID: 23674458
77. Eriksen JL, Przedborski S, Petrucelli L (2005) Gene dosage and pathogenesis of Parkinson's disease. Trends Mol Med 11:91-96. PMID: 15760766
78. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, et al. (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835-1838. PMID: 15159488
79. Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, et al. (2008) Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J 22:1327-1334. PMID: 18162487
80. Ulusoy A, Di Monte DA (2013) Alpha-synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. Mol Neurobiol 47:484-494. doi: 10.1007/s12035-012-8329-y PMID: 22944910